Table 1

Key studies of TNF-blocker therapy in rheumatoid arthritis, 52-week follow-up

Therapy

Disease stage

Reference

Primary outcome

Radiologic outcome

Infliximab

RA

Smolen and colleagues [16]

ACR20

Modified TSS

Infliximab

Early RA

Smolen and colleagues [17]

ACR20

Modified TSS

Etanercept

Early RA

Bathon and colleagues [18]

ACR20

TSS

Etanercept

RA

Klareskog and colleagues [19]

ACR20

Modified TSS

Etanercept

Early RA

Kekow and colleagues [20]

ACR20

Modified TSS

Adalimumab

Early RA

Breedveld and colleagues [21]

ACR50

Modified TSS

Adalimumab

RA

Keystone and colleagues [22]

ACR20

Modified TSS

Golimumab

RA

Kremer and colleagues [23]

ACR50

Modified TSS

Certolizumab

RA

Keystone and colleagues [24]

ACR20

Modified TSS

ACR20/50, American College of Rheumatology 20%/50% improvement; RA, rheumatoid arthritis; TSS, total Sharp score.

Schett et al. Arthritis Research & Therapy 2011 13(Suppl 1):S4   doi:10.1186/1478-6354-13-S1-S4